Eli Lilly's Recently Approved Inflammatory Bowel Disease Drug Shows Sustained And Durable Treatment At Two Years
Eli Lilly And Cao (NYSE:LLY) announced the results from the VIVID-2 open-label extension study of Omvoh (mirikizumab-mrkz).
The Oak Ridger on MSN5h
Your gut could play a major role in diseases: ORNL researcher to speak on gut microbiome
How the microbes in the human gut play roles in health and disease will be explored in a talk Tuesday, Feb. 11, by Robert "Bob" Hettich, corporate fellow and leader of the Bioanalytical Mass ...
The Brighterside of News on MSN19h
Keto diet improves multiple sclerosis, IBD and arthritis symptoms
Diet plays a pivotal role in influencing autoimmune diseases like multiple sclerosis (MS), inflammatory bowel disease, and ...
Mozart Therapeutics Presents Compelling New Preclinical Data on MTX-201 at the 2025 Crohn's and Colitis Congress®
Mozart Therapeutics, the leading developer of CD8 Treg network modulators in autoimmune disease, announces the presentation ...